• 5 min read
• Published on 25 July 2025
Listen to article
6:26Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
It strikes me as a bit like a star footballer deciding to leave a perfectly good Premier League club for the glamour and, let’s be honest, the colossal paycheques of a foreign league. The news that AstraZeneca, a titan of British industry, is reportedly mulling over a shift from the London Stock Exchange to Wall Street feels like a betrayal to some. To me, it just feels like inevitable, cold, hard business logic. And when a company of that stature gets restless, you can be sure others are quietly checking their own passports.
Let’s not beat around the bush. The core of this issue is money. European pharmaceutical giants are looking across the Atlantic and seeing their American cousins valued at far more generous multiples. It’s like two identical houses on the same street, but one is inexplicably priced 30 percent higher because it’s in a slightly trendier postcode. For a CEO and a board, whose job is to maximise shareholder value, that kind of discount becomes impossible to ignore.
AstraZeneca, for instance, earns a huge chunk of its revenue in the United States. Yet, its shares are priced according to the more, shall we say, reserved tastes of the London market. European investors have traditionally been a cautious bunch, valuing steady dividends over the speculative, high-growth narrative that American markets seem to adore. The question for these companies is simple: why stay where you’re merely appreciated, when you could go where you might be celebrated?
If this trend gathers steam, and I suspect it might, it could reshape the investment landscape. Imagine other European heavyweights, like Switzerland’s Novartis or France’s Sanofi, starting to feel the same gravitational pull. These are global players with massive American operations and drug pipelines that Wall Street would likely drool over. Remaining listed in Europe could start to look like a deliberate choice to leave money on the table.
The American market simply has a deeper understanding and a bigger appetite for the risks inherent in drug development. It’s home to a vast ecosystem of specialist biotech funds and healthcare analysts who live and breathe this stuff. They are more comfortable pricing in the potential of a blockbuster drug years before it hits the shelves. This creates a more dynamic, and often more generous, valuation environment. It’s a market built for the kind of high stakes poker that defines the pharmaceutical industry.
For those of us watching from the sidelines, this potential exodus presents a curious situation. On one hand, there’s the risk that comes with any major corporate upheaval. A transatlantic move is not a simple administrative task, it’s a complex and costly affair. On the other hand, there’s the potential for a significant revaluation for any company that successfully makes the leap.
The companies at the heart of this discussion are not flighty startups. They are established, cash-rich businesses that often pay reliable dividends, which is a comforting thought in choppy economic waters. The idea is that you could get the stability of a defensive stock combined with the potential upside of a major re-rating. It seems this trend has been noticed, with some thematic baskets like the Atlantic Shift being created to track these very companies. Of course, any investment carries risk and past performance is no guarantee of future results. One must always do their own homework.
View the full Basket:The Atlantic Shift: Pharma's US Listing Trend
View the full Basket:The Atlantic Shift: Pharma's US Listing Trend
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article